Amendment in response to OA of April 28, 2009

Amendments to the Claims:

Please amend the claims:

(currently amended) A combination vaccine for the protection of poultry against

Ornithobacterium rhinotracheale, wherein said combination vaccine comprises a live over-

attenuated Ornithobacterium rhinotracheale strain and a live attenuated poultry virus, and wherein

said live, over-attenuated Ornithobacterium rhinotracheale strain is not capable of inducing a

protective immune response to Ornithobacterium rhinotracheale in animals primed with a

virulent pathogen.

2. (previously presented) The combination vaccine according to claim 1, wherein said live

attenuated poultry virus is Infectious Bronchitis virus, Newcastle Disease virus, Turkey

Rhinotracheitis virus, Marek's virus or Avian Reovirus.

3. (previously presented) The combination vaccine according to claim 1, wherein said live

attenuated poultry virus is Infectious Bronchitis virus, Newcastle Disease virus or Turkey

Rhinotracheitis virus.

4. (previously presented) The combination vaccine according to claim 1, wherein said live

attenuated poultry virus is Newcastle Disease virus.

(previously presented) The combination vaccine according to claim 1, wherein said live

attenuated poultry virus is Newcastle Disease virus type NDC2.

(previously presented) The combination vaccine according to claim 1, wherein said live

attenuated poultry virus is Turkey Rhinotracheitis virus.

(previously presented) The combination vaccine according to claim 1, wherein said live

attenuated poultry virus is Infectious Bronchitis virus.

Page 6 of 10

Attorney Docket: -2003.025 US

USSN 10/582,315

Amendment in response to OA of April 28, 2009

- 8. (currently amended) The combination vaccine according to claim 1 wherein said live overattenuated *Ornithobacterium rhinotracheale* has a mutation, said mutation preferably being a deletion in the *purD*-gene or the *recA*-gene that reduces the activity of those genes.
- 9. (currently amended) The combination vaccine according to claim 1, wherein said combination vaccine comprises an additional antigen **derived** from a virus or micro-organism pathogenic to poultry or genetic information encoding said antigen.
- 10. (previously presented) The combination vaccine according to claim 9, wherein the virus or micro-organism is selected from the group consisting of Infectious Bronchitis virus, Infectious Bursal Disease (Gumboro), Chicken Anaemia agent, Avian Reovirus, *Mycoplasma gallisepticum*, Turkey Rhinotracheitis virus, *Haemophilus paragallinarum* (Coryza), Chicken Poxvirus, Avian Encephalomyelitisvirus, Duck Plague virus, Egg Drop syndrome virus, Infectious Laryngotracheitis virus, Herpes Virus of Turkeys, Eimeria species, *Ornithobacterium rhinotracheale, Pasteurella multocida, Mycoplasma synoviae, Salmonella* species and *E. coli*.
- 11. (currently amended) A method of protecting -poultry against *Ornithobacterium* rhinotracheale comprising administering [[a]] the combination vaccine of claim 1. comprising live-over-attenuated Ornithobacterium rhinotracheale strain and a live attenuated poultry virus.
- 12. (previously presented) The method according to claim 11, wherein the live over-attenuated *Ornithobacterium rhinotracheale* strain and the live attenuated poultry virus are administered simultaneously, separately or sequentially.
- 13. (previously presented) A method for preparing the combination vaccine according to claim 1 wherein said method comprises the admixing of a live over-attenuated *Ornithobacterium* rhinotracheale strain, a live attenuated poultry virus and a pharmaceutically acceptable carrier.

Attorney Docket: -2003.025 US USSN 10/582,315 Amendment in response to OA of April 28, 2009

14. (currently amended) A vaccination kit for the immunization of poultry against *Ornithobacterium rhinotracheale*, wherein said kit comprises

- a) a live over-attenuated Ornithobacterium rhinotracheale strain,
- b) a live attenuated poultry virus,
- c) optionally a pharmaceutically acceptable carrier for (a); and
- d) optionally-a pharmaceutically acceptable carrier for (b).
- 15. (previously presented) A vaccination kit according to claim 14, wherein the carrier of (c) or (d) comprises an adjuvant.